Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$2.05 - $2.99 $427,019 - $622,822
-208,302 Reduced 42.0%
287,698 $817,000
Q3 2023

Nov 14, 2023

BUY
$2.56 - $4.4 $1.27 Million - $2.18 Million
496,000 New
496,000 $1.28 Million

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Altium Capital Management LP Portfolio

Follow Altium Capital Management LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Altium Capital Management LP with notifications on news.